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BACKGROUND AND PURPOSE—The Safety and Efficacy of NeuroFlo Technology in
Ischemic Stroke trial showed a trend for reduced all-cause mortality and positive secondary safety
end point outcomes. We present further analyses of the mortality and severe disability data from
the Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke trial.
MATERIALS AND METHODS—The Safety and Efficacy of NeuroFlo Technology in Ischemic
Stroke trial was a multicenter, randomized, controlled trial that evaluated the safety and
effectiveness of the NeuroFlo catheter in patients with stroke. The current analysis was performed
on the as-treated population. All-cause and stroke-related mortality rates at 90 days were
compared between groups, and logistic regression models were fit to obtain ORs and 95% CIs for
the treated versus not-treated groups. We categorized death-associated serious adverse events as
neurologic versus non-neurologic events and performed multiple logistic regression analyses. We
analyzed severe disability and mortality by outcomes of the mRS. Patient allocation was gathered
by use of a poststudy survey.
RESULTS—All-cause mortality trended in favor of treated patients (11.5% versus 16.1%; P = .
079) and stroke-related mortality was significantly reduced in treated patients (7.5% versus
14.2%; P = .009). Logistic regression analysis for freedom from stroke-related mortality favored
treatment (OR, 2.41; 95% CI, 1.22, 4.77; P = .012). Treated patients had numerically fewer
neurologic causes of stroke-related deaths (52.9% versus 73.0%; P = .214). Among the 90-day
survivors, nominally fewer treated patients were severely disabled (mRS 5) (5.6% versus 7.5%;
OR, 1.72; 95% CI, 0.72, 4.14; P = .223). Differences in allocation of care did not account for the
reduced mortality rates.
CONCLUSIONS—There were consistent reductions in all-cause and stroke-related mortality in
the NeuroFlo-treated patients. This reduction in mortality did not result in an increase in severe
disability.
Recently, the primary results of the Safety and Efficacy of NeuroFlo Technology in
Ischemic Stroke (SENTIS) trial have been published.1 NeuroFlo therapy involves partial
occlusion of the abdominal aorta that results in a prompt increase in blood volume above the
partial occlusion and has been shown to specifically increase CBF by diverting blood flow
from the lower limbs to the brain.2 Preclinical studies in animal models and imaging studies
in patients indicate that this intervention creates a substantial increase in CBF that persists
beyond deflation and removal of the NeuroFlo device without an increase in intracerebral
hemorrhages.1,3 A feasibility study in 25 patients with ischemic stroke treated up to 24 hours
after symptom onset also showed no parenchymal hematomas and no symptomatic
intracerebral hemorrhages.4 For an extensive review of the literature and mode of action, we
refer to a recent review by Liebeskind et al.5
SENTIS was a prospective, randomized, multicenter trial to evaluate the safety and efficacy
of CBF augmentation in patients with acute ischemic stroke who were able to have
NeuroFlo treatment initiated within 14 hours of the onset of symptoms. SENTIS was the
first randomized trial of an interventional device for stroke with a primary clinical outcomes
end point, a global disability outcome assessment that is based on an excellent outcome on a
combination of several scales (Barthel Index, National Institutes of Health Stroke Scale
Score [NIHSSS], mRS, and Glasgow Outcome Scale). In the intent-to-treat analysis, the
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SENTIS results did not achieve statistical significance for the primary efficacy end point:
(OR, 1.17; 95% CI, 0.81–1.67; P = .407). The primary safety end point was met: There was
no difference in serious adverse events between groups (P = .923). A statistical trend for all-
cause mortality and positive secondary safety end point outcomes was observed.1
Additionally, post hoc analyses have shown positive results, especially with regard to
stroke-related mortality. In this report, we present further analyses of the mortality and
severe disability data from the SENTIS trial.
MATERIALS AND METHODS
For detailed methods of the trial, we refer to the original publication of the SENTIS trial
(ClinicalTrials.gov, No. NCT00119717).1 The trial was funded by CoAxia. All authors
vouch for the accuracy and completeness of the data and analysis. All authors had access to
all the data in the study and had final responsibility for submission of this publication.
Briefly, patients who met all of the enrollment criteria and provided written consent were
allocated to NeuroFlo treatment with standard medical management (treatment) or standard
medical management alone (control) through the use of a 1:1 randomization scheme that
was stratified by site, baseline NIHSSS, and the time from symptom onset. All patients were
followed for safety and efficacy through 90 days; formal clinical assessments were
performed at 6 and 24 hours and at 4 (or hospital discharge, if earlier), 30, and 90 days. The
final 90-day assessment was blinded. Follow-up cranial CT imaging was performed at 24
hours and, in cases of neurologic worsening, at any time up to 90 days. Additionally, a
poststudy survey was completed to gather information on patient treatment unit allocation
(admission to neuro/stroke intensive care unit, other intensive care unit, stroke unit, or
general unit) and the presence of “do not resuscitate”/”do not intubate,” and “comfort care
only” orders.
Statistical Analyses
All analyses were performed on the “modified as-treated” population.1 Standard summary
statistics were calculated for all study variables. Categoric variables were summarized by the
use of frequency distributions and 95% CIs.
The proportions of patients with all-cause and stroke-related mortality were compared
between groups by use of a Cochran-Mantel-Haenszel test, stratified by age and baseline
NIHSSS. Logistic regression models were also fit for all-cause and stroke-related mortality
to obtain an OR and 95% CI for the treated versus not-treated comparison. Kaplan-Meier
curves for stroke-related mortality were provided, along with estimates at specific time
points (4, 30, 60, and 90 days) and their associated 95% CIs.
We qualitatively reviewed the serious adverse events related to deaths categorized into
neurologic versus non-neurologic events and performed multiple logistic regression analyses
for influence of baseline stroke severity (NIHSSS) and allocation of treatment location/unit.
Schellinger et al. Page 3






















We analyzed the severe disability and mortality data by dichotomized (mRS 0–4 versus 5),
tetrachotomized (mRS 0–2, 3–4, 5, 6), and full-scale (mRS 0, 1, 2, 3, 4, 5, 6) outcomes of
the mRS.
All statistical tests, including those comparing the treatment groups for mortality, stroke-
related mortality, and allocation to treatment location, are 2-sided. Statistical analyses were
conducted in SAS version 9.1 or above (SAS Institute, Cary, North Carolina).
RESULTS
Between October 2005 and January 2010, 515 patients were enrolled in the SENTIS trial at
68 centers. A total of 257 patients were randomly assigned to the control group and 258
patients were randomly assigned to the treatment group (intention-to-treat population).
Twenty-eight patients randomly assigned to treatment were excluded because of
prespecified criteria, 5 patients randomly assigned to treatment did not receive treatment,
and 1 patient randomly assigned to the control group received NeuroFlo treatment (both
were protocol deviations), resulting in 261 not-treated patients and 226 treated patients in
the “modified as-treated” analysis.1
Mortality
All-cause mortality rates (intention to treat: 11.2% versus 16.3%; OR, 1.60; 95% CI, 0.91–
2.83; P = .086; modified intention to treat: 11.3% versus 16.3%; OR, 1.56; 95% CI, 0.87–
2.80; P = .087), and stroke-related mortality (intention to treat: 7.8% versus 14.4%; OR,
2.45; 95% CI, 1.25–4.79; P = .009; modified intention to treat: 7.4% versus 14.4%; OR,
2.53; 95% CI, 1.25–5.09; P = .010) rates did not differ between the intention to treat,
modified intention to treat, and the from here on presented “modified as-treated” populations
in treatment versus control patients.
As reported in the primary results, all-cause mortality (“modified as-treated”) trended in
favor of treated patients (P = .079); by the 90-day follow-up visit, 11.5% (26/226) in the
treated group and 16.1% (42/261) in the not-treated group had died.1 Stroke-related
mortality differed significantly between groups, again in favor of treated patients: 7.5%
(17/226) treated versus 14.2% (37/261) not treated (95% CI −12.1, −1.2; P = .009). Most
(85%) of the stroke-related deaths occurred within 30 days of the index stroke. The logistic
regression analysis for freedom from stroke-related mortality, adjusted by baseline NIHSSS
and age, favored treatment, with an OR of 2.41 (95% CI, 1.22, 4.77; P = .012). Fig 1 shows
the Kaplan-Meier curve for freedom from stroke-related mortality.
Primary Causes of Stroke-Related Deaths
For a full listing and definitions of stroke-related versus not stroke-related mortality, see
Table 4 of the original SENTIS publication.1 Although the absolute numbers for each cause
of stroke-related death were too few for any differences between arms to reach statistical
significance, treated patients numerically had fewer stroke-related deaths for all causes
except renal causes. Most notably, stroke-related deaths from neurologic causes (eg,
bleeding, stroke progression, edema, new strokes) were numerically fewer in treated versus
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not-treated patients (treated: 9/17, 52.9%; non-treated: 27/37, 73.0%; P = .214) as opposed
to other reasons for death (eg, cardiac, renal, pulmonary, multi-organ failure, sepsis).
Severe Disability
The trend toward reduced all-cause mortality, mainly driven by a significantly reduced
stroke-related mortality, did not come at the cost of an increased rate of severe disability.
Among the survivors at the 90-day follow-up, fewer of the treated (5.6%, 11/195) patients
than the control patients (7.5%, 16/212) were severely disabled (mRS score =5). The
absolute difference (1.9%) was not statistically significant in either univariate or
multivariate analyses (OR, 0.58; 95% CI, 0.24, 1.39; P = .223). As shown in Fig 2,
compared with the not-treated group, the treated group had more patients in the lower range
of the mRS scores and fewer with scores that indicate death (mRS 6) and severe disability
(mRS 5). This suggests that after NeuroFlo treatment, patients who may have otherwise died
(mRS 6) or been severely disabled (mRS 5) were more likely to survive with moderate or
mild disability. Additionally, patients who may have been moderately disabled (mRS 3–4)
were shifted toward an independent outcome (mRS 0–2).
First Site of Care
A total of 437 of 515 (85%) poststudy surveys were returned with evaluable data regarding
first site of care; 204 of 226 for treated patients and 233 of 261 for control patients. The
survey suggested differences in the first site of care between treatment arms with nominally
more treated patients admitted before the procedure to a stroke- or neuro-intensive care unit
than not-treated patients (Table 1). When all intensive care units were combined, the
numbers were significant, with an absolute difference of 13.5% (60.3% versus 46.8%, P = .
005). Conversely, more patients from the not-treated arm were admitted to general wards as
their first site of care. When these variables were included in the multivariate analysis, first
site of care was not a predictor of mortality, stroke-related mortality, or independent
outcome categorized as mRS 0–2 versus 3–6. Furthermore, when the outcome of all-cause
mortality is analyzed by the first site of care, the treated group had lower rates of mortality
(8.5–23.1%) than the not-treated group (14.4–20.6%) for all sites of care except for general
unit (treated, 23.1% versus not treated, 20.6%; P = 1.000) (Table 2). Similarly, the stroke-
related mortality rate was also nominally lower in the treated group (7.3–15.4%) compared
with the not-treated group (11.1–17.7%) for all first sites of care except general unit (treated,
15.4% versus not treated, 14.7%; P = 1.000) (Table 3). Therefore, the differences in
allocation of care do not account for the reduced mortality rates among the treated patients.
Do Not Resuscitate/Do Not Intubate and Withdrawal of Care Orders
The numbers for do not resuscitate/intubate, and comfort care orders did not differ between
treatment and control patients: 10.3% (21/204) versus 11.7% (28/239) (Fisher exact test, P
= .652), and 6.9% (14/204) versus 10.5% (25/239) (P = .239). Death was highly associated
with the presence of these orders (OR, 22.96; 95% CI, 8.5, 62.3; P < .0001) and comfort
care orders (OR, 77.33; 95% CI, 23.3, 218.5; P < .0001). The median number of days
between initiation of the orders and death was 2.0 days for do not resuscitate/intubate orders
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and 2.5 days for comfort care orders; there was no difference between treated and not-
treated patients.
DISCUSSION
The SENTIS trial tested the clinical efficacy and safety of the NeuroFlo device, which, by
increasing cerebral blood flow to ischemic brain, was hypothesized to lead to reduced
morbidity and mortality in patients with acute stroke treated within 14 hours after onset of
symptom.1 SENTIS established safety for the NeuroFlo procedure but missed statistical
significance for the primary clinical outcome end point. While the use of the global outcome
end point and also dichotomized end points of the mRS have been a matter of recent
debate,6–8 the currently favored mRS shift analysis over the full range of the ordinal scale
did not render a different trial result.1 An intriguing and important observation in the
SENTIS trial was a trend for reduced overall mortality. This reduction was driven by a
significantly lower stroke-related mortality rate among treated patients. Death rates from
stroke, stroke-related complications, and new strokes were all nominally lower in the treated
patients. Notably, the reduction in the death rate was not accompanied by an increase in the
proportion of patients who were severely disabled. Additionally, these findings were not
related to the first site of care or withdrawal of care in treated versus not-treated patients.
Albeit dealing with post hoc analyses, these results shed more light on the findings from
SENTIS. It is apparent that the trend in reduced all-cause mortality was for the most part a
result of reduced stroke-related mortality. Hemodynamic augmentation by partial aortic
occlusion results in a varying increase of CBF by approximately 30%, an effect that lasts
beyond the procedure itself.5 Although further analysis of the acquired imaging data are
necessary, this may lead to improved collateral flow to ischemic penumbral brain and
thereby reduce infarct size in treated patients as compared with control subjects. Stroke size
has been repeatedly established as a predictor for outcome and mortality.9–12 Both direct
stroke-related complications (eg, space-occupying infarction with increased intracranial
pressure, edema) and secondary disability-associated complications (eg, deep venous
thrombosis, infections, aspiration) may be reduced as a result of a smaller final infarct size.
Although SENTIS was not powered to detect the effect on overall clinical outcome
measured with the mRS, the mortality findings are encouraging and may be useful in
designing further studies. Some of the promising approaches with other acute stroke
treatments that have been studied in pilot trials are the use of partial aortic occlusion as an
adjunct to standard rtPA (FastFlo)3 and in extended time windows (Flo24).4 In both trials,
feasibility and safety could be demonstrated. A larger NeuroFlo device with a central lumen
has been developed, which could allow for intraarterial treatment and/or thrombectomy in
parallel to partial aortic occlusion and flow improvement. The latter has not been tested in a
pilot trial.
A frequently disputed ethical as well as economic issue is whether a therapeutic procedure
reduces mortality at the cost of increasing severe disability in survivors.13 In SENTIS, the
reduction in mortality did not result in an increase in severe disability as measured by the
mRS. This is not explained by a difference in the rate of serious adverse advents between the
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2 arms and illustrates an overall shift toward better outcomes in the treatment arm, an effect
also observed in the hemicraniectomy trials.14
Potential confounding variables in assessing mortality outcomes in stroke trials are
variability in admission to intensive care units and stroke units and variability in the
application of do not resuscitate or intubate orders and compassionate care, a frequent
phenomenon especially among victims of ischemic stroke and hemorrhagic stroke.15 It is
theoretically possible, in interventional trials unblinded for the treatment arm and only
blinded for the outcome assessment (PROBE design), that actively treated patients may
more frequently receive specialized care and allocation to intensive care and stroke units,
leading to self-fulfilling results. In a poststudy survey, we acquired further data regarding
site of care and do not resuscitate/intubate orders not originally obtained for the SENTIS
trial itself. There were no major differences with regard to treatment allocation or do not
resuscitate/intubate orders; however, more patients treated with NeuroFlo were assigned to
stroke units and neuro-intensive care units. This difference in first site of care may be due in
part to standard of care procedures and hospital protocols that often require intensive care
unit admission after any endovascular procedure. Despite the allocation imbalance, in
treated patients, both the all-cause and stroke-related mortality rates were nominally lower in
all but one allocation (general ward), where they were nearly identical. Finally, first
treatment site was not an independent predictor of outcome in the multivariate analysis.
Among the limitations of our analyses are the inclusion of post hoc analyses and the use of a
poststudy survey, though the latter was submitted for 85% of the study patients. Despite
these limitations, we believe that the significant reduction in stroke-related mortality in the
SENTIS trial is an indication of potential efficacy of the therapeutic approach. We did not
find other explanations for this observation and therefore do not believe this to arise from
confounds in sites of or intensity of care, though SENTIS was ultimately not powered for
the predefined end point. We believe that the therapeutic approach of hemodynamic
augmentation merits further study because the efficacy results are promising and safety is
established.
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Kaplan-Meier curve: Freedom from stroke-related mortality.
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Modified Rankin shift for SENTIS as-treated population. *Values within the shift analysis
are based on 90-day evaluable patients.
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Table 1
First site of care
First Site of Care
Treated Not Treated
P Value (Fisher Exact)
N = 204 N = 233
n = 25 n = 38
Neuro/Stroke ICU 40.2% (82/204) 32.2% (75/233) .090
Other ICU 20.1% (41/204) 14.6% (34/233) .162
Stroke unit 33.3% (68/204) 38.6% (90/233) .273
General unit 6.4% (13/204) 14.6% (34/233) .008
Any ICUa 60.3% (123/204) 46.8% (109/233) .005
Note:—N indicates total number of surveys received with evaluable data for first site of care; n, number of patients with evaluable surveys who
died.
a
Any ICU is the combination of the Neuro/Stroke ICU and Other ICU.
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Table 2
All-cause mortality rate by first site of care
First Site of Care
Treated Not Treated
P Value (Fisher Exact)
N = 204 N = 233
n = 25 n = 38
Neuro/Stroke ICU 8.5% (7/82) 16.0% (12/75) .220
Other ICU 14.6% (6/41) 17.7% (6/34) .760
Stroke unit 13.2% (9/68) 14.4% (13/90) 1.000
General unit 23.1% (3/13) 20.6% (7/34) 1.000
Total mortality rate 12.3% 16.3% .275
Note:—N indicates total number of surveys received with evaluable data for first site of care; n, number of patients with evaluable surveys who
died.
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Table 3
Stroke-related mortality rate by first site of care
First Site of Care
Treated Not Treated
P Value (Fisher Exact)
N = 204 N = 233
n = 17 n = 33
Neuro/Stroke ICU 7.3% (6/82) 16.0% (12/75) .131
Other ICU 7.3% (3/41) 17.7% (6/34) .285
Stroke unit 8.8% (6/68) 11.1% (10/90) .792
General unit 15.4% (2/13) 14.7% (5/34) 1.000
Total stroke-related mortality rate 8.3% 14.2% .070
Note:—N indicates total number of surveys received with evaluable data for first site of care; n, number of patients with evaluable surveys who
died of stroke-related causes.
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